J&J Covid-19 Vaccine was paused over Blood-Clotting Issues

The health authorities of the United States came close to simply warning about the Blood-Clotting risk of the Johnson & Johnson vaccine. However, they decided to recommend pausing the usage of the vaccine out of concern doctors would improperly treat the condition. Over the previous four weeks, American health officials had become alarmed about the similar Blood-Clotting conditions in Europe related to the vaccine from AstraZeneca PLC.

The US vaccine safety database was dug out and identified by the cases of great concern but they were debated of what action needs to be taken. Last Monday night, the officials said that urgent action was required. Four out of six women in the US developed the blood clots days after the vaccination had received heparin before it. People said that its use could have worsened the condition of the patient.

The top health officials of the country agreed during the one-hour Zoom meeting to take the strongest step. It was publicly recommended to pause the vaccine’s use till probing the adverse-event cases. After the announcement, the Food and Drug Administration has been studying reports related to Blood-Clotting cases among other people who received the J&J vaccine. However, confirmation is yet to come whether they reflect the same phenomenon.

Yet, the officials are being persuaded that the six total cases reported so far are related to the shot. FDA officials are waiting to see what the vaccine panel recommends to the CDC. The two most likely options are restricting the use of the shot to an age group of men and women above 50 years.